Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27527945 | 0.87 | LMNA (0.46) | ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL22014538 | 0.85 | OPRM1 (0.52) | ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL11368685 | 0.85 | ALDH1A1 (0.53) | ALDH1A1KMT2A | |
| SCHEMBL3556103 | 0.84 | CYP2C19 (0.47) | ALDH1A1MEN1KMT2ACYP2C19SMN1; SMN2 | |
| SCHEMBL22014536 | 0.83 | TACR1 (0.48) | ALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL3563828 | 0.81 | MEN1 (0.56) | MEN1KMT2ANPSR1 | |
| SCHEMBL22014537 | 0.79 | OPRM1 (0.51) | ALDH1A1 | |
| SCHEMBL28893494 | 0.78 | MEN1 (0.50) | ALDH1A1MEN1KMT2ACYP2C19SMN1; SMN2 | |
| SCHEMBL21963898 | 0.78 | DDB1 (0.43) | MEN1KMT2ALMNA | |
| SCHEMBL16875463 | 0.76 | SMN1; SMN2 (0.52) | ALDH1A1CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | ALDH1A1 2078/4885MEN1 1845/4885KMT2A 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.